Daniel from Improve Press
RNA-focused digital therapeutics firm Flamingo Therapeutics added a brand new member to its board of administrators, Dr. Ezra Cohen.
Flamingo produces RNA therapies for oncology and is backed by traders corresponding to Andera Companions, Bpifrance Giant Enterprise, Perceptive Advisors, Sphera and VIB.
Dr. Cohen has a historical past within the improvement of prescribed drugs, particularly head and neck cancers.
“The science and workforce at Flamingo are very spectacular, and I’m excited to affix the board following the latest initiation of a number of vital oncology medical research. I consider that Flamingo is uniquely positioned to enhance the top and neck therapy panorama with its RNA-targeting strategy, and I look ahead to working with the workforce to ship new therapeutic choices for sufferers,” Dr. Cohen mentioned in an announcement.
Life sciences software program firm Synthace introduced the appointment of Willem Baralt as its new chairman of the board. Baralt joined the corporate in February.
Synthace helps R&D scientists via automation throughout numerous levels, together with experimental design, simulations and the creation of complete digital data.
Baralt has served on a number of boards of healthcare and charitable organizations. Most just lately, he served at moveable dialysis machine maker Quanta Dialysis Applied sciences, which secured $245 million in Collection D funding in 2021.
“I’m really honored to affix the Synthace workforce at this time limit as it’s trying to remodel the life sciences R&D panorama. With its digital experimentation platform, Synthace empowers scientists to design and execute experiments that have been beforehand inconceivable. Synthace’s know-how is essential to enabling the R&D lab of the long run, permitting its prospects to make new therapies whereas attaining radical time and value financial savings,” Mr. Baralt mentioned in an announcement.
